(MD) Mednax - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061
MD: Newborn Care, Maternal-Fetal Care, Pediatric Care
Pediatrix Medical Group, Inc. (NYSE: MD), formerly known as MEDNAX, Inc., is a leading provider of specialized pediatric and maternal-fetal healthcare services in the United States. Founded in 1979 and headquartered in Sunrise, Florida, the company operates through its subsidiaries to deliver critical care services across multiple clinical settings. Its core offerings include neonatal care for premature or critically ill newborns, maternal-fetal medicine for high-risk pregnancies, and a range of pediatric subspecialty services. The company employs a multidisciplinary team of neonatologists, pediatric intensivists, maternal-fetal medicine specialists, and other healthcare professionals to provide comprehensive care in hospitals, nurseries, and outpatient clinics. Pediatrix Medical Group also offers newborn hearing screening programs and support services in pediatric emergency rooms, labor and delivery units, and other hospital departments. The companys services are designed to address the complex medical needs of newborns, expectant mothers, and children, leveraging advanced clinical protocols and technology to improve patient outcomes.
From a technical perspective, Pediatrix Medical Groups stock (NYSE: MD) has shown stable price action, with its 20-day moving average at 12.91 closely aligning with its last price of 12.94. The 50-day moving average at 13.88 and 200-day moving average at 12.82 suggest a slight downtrend over the medium term. The average true range (ATR) of 0.59 indicates moderate volatility. On the fundamental side, the companys market cap of $1.1 billion reflects its established presence in the healthcare services sector. The forward P/E of 8.24 points to potential undervaluation, though the negative return on equity (-12.95) raises concerns about profitability. The price-to-book ratio of 1.44 and price-to-sales ratio of 0.55 suggest the stock may offer value for investors willing to overlook short-term financial challenges. Overall, Pediatrix Medical Groups stock is positioned for stability with upside potential, supported by its essential healthcare services and attractive valuations.
Additional Sources for MD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MD Stock Overview
Market Cap in USD | 1,110m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1995-09-19 |
MD Stock Ratings
Growth Rating | -6.36 |
Fundamental | 4.02 |
Dividend Rating | 0.0 |
Rel. Strength | 77.1 |
Analysts | 3.75/5 |
Fair Price Momentum | 14.79 USD |
Fair Price DCF | 48.36 USD |
MD Dividends
No Dividends PaidMD Growth Ratios
Growth Correlation 3m | -59.5% |
Growth Correlation 12m | 78.1% |
Growth Correlation 5y | -75.2% |
CAGR 5y | 0.45% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | 0.26 |
Alpha | 62.68 |
Beta | 0.465 |
Volatility | 41.34% |
Current Volume | 1580.3k |
Average Volume 20d | 511.9k |
As of May 09, 2025, the stock is trading at USD 14.44 with a total of 1,580,307 shares traded.
Over the past week, the price has changed by +13.34%, over one month by +8.82%, over three months by +3.29% and over the past year by +69.88%.
Neither. Based on ValueRay Fundamental Analyses, Mednax is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 4.02 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MD as of May 2025 is 14.79. This means that MD is currently overvalued and has a potential downside of 2.42%.
Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.
- Strong Buy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, MD Mednax will be worth about 16 in May 2026. The stock is currently trading at 14.44. This means that the stock has a potential upside of +10.66%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 18.1 | 25.1% |
Analysts Target Price | 18.1 | 25.1% |
ValueRay Target Price | 16 | 10.7% |